Company news
Clinuvel Pharmaceuticals Limited (ASX:CUV) news
Every Clinuvel Pharmaceuticals Limited press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 3
CLINUVEL hosts European EPP Expert Meeting
March 18, 2018
Preliminary assessment received from NICE
December 20, 2017
CLINUVEL provides update on SCENESSE FDA filing
September 18, 2017
Preliminary Final Report
August 30, 2017
Amended Appendix 4C - quarterly
July 31, 2017
NICE England Update on SCENESSE
May 1, 2017
CLINUVEL reaches agreement on German SCENESSE pricing
April 12, 2017
CLINUVEL agrees with FDA on New Drug Application timelines
November 8, 2016
SCENESSE - NICE England Update
October 17, 2016
FDA Schedules Pre-NDA Meeting for SCENESSE
October 12, 2016
Clinuvel completes combination therapy pre-clinical study
August 3, 2016
FDA accept SCENESSE clinical data package for NDA submission
July 18, 2016
FDA awards SCENESSE Fast Track designation for EPP treatment
July 5, 2016
SCENESSE launched in Europe
June 22, 2016
SCENESSE Treatment in Europe
May 18, 2016
SCENESSE attains breakthrough European Market Authorisation
March 30, 2016
Clinuvel accredits first European EPP expert centres
March 14, 2016
Clinuvel brief on European commercialisation
February 15, 2016
US FDA orphan designation received for cutaneous porphyrias
February 11, 2016
Update on North American vitiligo program for SCENESSE
February 10, 2016